company background image
8158

China Regenerative Medicine International SEHK:8158 Stock Report

Last Price

HK$0.12

Market Cap

HK$353.9m

7D

-24.8%

1Y

-55.2%

Updated

29 Sep, 2022

Data

Company Financials
8158 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

8158 Stock Overview

China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services.

China Regenerative Medicine International Competitors

Price History & Performance

Summary of all time highs, changes and price drops for China Regenerative Medicine International
Historical stock prices
Current Share PriceHK$0.12
52 Week HighHK$0.35
52 Week LowHK$0.12
Beta2.14
1 Month Change-28.82%
3 Month Change-34.60%
1 Year Change-55.18%
3 Year Change-13.57%
5 Year Change-96.98%
Change since IPO-91.36%

Recent News & Updates

Shareholder Returns

8158HK BiotechsHK Market
7D-24.8%-2.4%-5.4%
1Y-55.2%-60.1%-28.0%

Return vs Industry: 8158 exceeded the Hong Kong Biotechs industry which returned -60.1% over the past year.

Return vs Market: 8158 underperformed the Hong Kong Market which returned -28% over the past year.

Price Volatility

Is 8158's price volatile compared to industry and market?
8158 volatility
8158 Average Weekly Movement9.5%
Biotechs Industry Average Movement8.3%
Market Average Movement6.4%
10% most volatile stocks in HK Market12.5%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 8158 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 8158's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
199524Chuang Wanghttps://www.crmi.hk

China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services. The company offers health management services, such as assessment of health situation, treatment for detox, balance of inner body, nourishing organs, and enhancement of immune system; and beauty services comprising non-surgical medical aesthetic services, basic skincare, solutions for youthful skin, hair revitalizing, lines firming, partial remodelling, and intimate repairing services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015.

China Regenerative Medicine International Fundamentals Summary

How do China Regenerative Medicine International's earnings and revenue compare to its market cap?
8158 fundamental statistics
Market CapHK$353.93m
Earnings (TTM)HK$26.06m
Revenue (TTM)HK$253.85m

13.3x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
8158 income statement (TTM)
RevenueHK$253.85m
Cost of RevenueHK$194.34m
Gross ProfitHK$59.52m
Other ExpensesHK$33.45m
EarningsHK$26.06m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.0091
Gross Margin23.44%
Net Profit Margin10.27%
Debt/Equity Ratio33.6%

How did 8158 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 8158 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8158?

Other financial metrics that can be useful for relative valuation.

8158 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA10.9x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 8158's PE Ratio compare to its peers?

8158 PE Ratio vs Peers
The above table shows the PE ratio for 8158 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average20.7x
1061 Essex Bio-Technology
5.8x15.0%HK$1.9b
775 CK Life Sciences Int'l. (Holdings)
46.8xn/aHK$6.0b
6826 Shanghai Haohai Biological Technology
22.9x34.3%HK$11.1b
1530 3SBio
7.1x-1.1%HK$13.5b
8158 China Regenerative Medicine International
13.3xn/aHK$353.9m

Price-To-Earnings vs Peers: 8158 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the peer average (20.7x).


Price to Earnings Ratio vs Industry

How does 8158's PE Ratio compare vs other companies in the Asian Biotechs Industry?

Price-To-Earnings vs Industry: 8158 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the Asian Biotechs industry average (27.1x)


Price to Earnings Ratio vs Fair Ratio

What is 8158's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8158 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8158's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 8158 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 8158's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 8158's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is China Regenerative Medicine International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


56.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Regenerative Medicine International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has China Regenerative Medicine International performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


27.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 8158 has a high level of non-cash earnings.

Growing Profit Margin: 8158 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 8158 has become profitable over the past 5 years, growing earnings by 27.7% per year.

Accelerating Growth: 8158 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 8158 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (10.2%).


Return on Equity

High ROE: 8158's Return on Equity (23.5%) is considered high.


Discover strong past performing companies

Financial Health

How is China Regenerative Medicine International's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 8158's short term assets (HK$259.2M) exceed its short term liabilities (HK$157.8M).

Long Term Liabilities: 8158's short term assets (HK$259.2M) exceed its long term liabilities (HK$17.0M).


Debt to Equity History and Analysis

Debt Level: 8158's net debt to equity ratio (30.9%) is considered satisfactory.

Reducing Debt: 8158's debt to equity ratio has reduced from 39.5% to 33.6% over the past 5 years.

Debt Coverage: 8158's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 8158's interest payments on its debt are well covered by EBIT (101.4x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is China Regenerative Medicine International current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

China Regenerative Medicine International Dividend Yield vs Market
How does China Regenerative Medicine International dividend yield compare to the market?
SegmentDividend Yield
Company (China Regenerative Medicine International)n/a
Market Bottom 25% (HK)3.0%
Market Top 25% (HK)8.8%
Industry Average (Biotechs)1.0%
Analyst forecast in 3 Years (China Regenerative Medicine International)n/a

Notable Dividend: Unable to evaluate 8158's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8158's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8158's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8158's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 8158 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Chuang Wang (42 yo)

2.92yrs

Tenure

HK$1,200,000

Compensation

Mr. Chuang Wang has been Executive Chairman at China Regenerative Medicine International Limited since October 18, 2019 and serves as its Chief Executive Officer since July 9, 2020 and also serves as its C...


CEO Compensation Analysis

Chuang Wang's Compensation vs China Regenerative Medicine International Earnings
How has Chuang Wang's remuneration changed compared to China Regenerative Medicine International's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

HK$26m

Mar 31 2022n/an/a

HK$49m

Dec 31 2021HK$1mn/a

HK$52m

Sep 30 2021n/an/a

-HK$230m

Jun 30 2021n/an/a

-HK$82m

Mar 31 2021n/an/a

-HK$105m

Dec 31 2020HK$1mn/a

-HK$120m

Sep 30 2020n/an/a

-HK$201m

Jun 30 2020n/an/a

-HK$237m

Mar 31 2020n/an/a

-HK$239m

Dec 31 2019HK$245kHK$245k

-HK$264m

Compensation vs Market: Chuang's total compensation ($USD152.87K) is below average for companies of similar size in the Hong Kong market ($USD241.94K).

Compensation vs Earnings: Chuang's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 8158's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: 8158's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 8158 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SEHK:8158 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Sep 22BuyHK$458,141Chuang WangIndividual2,695,000HK$0.17
07 Sep 22BuyHK$510,969Chuang WangIndividual3,080,000HK$0.17
05 Sep 22BuyHK$511,494Chuang WangIndividual3,100,000HK$0.16
26 Aug 22BuyHK$493,847Chuang WangIndividual2,975,000HK$0.17

Ownership Breakdown

What is the ownership structure of 8158?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders722,225,00025.3%
Private Companies1,005,547,76535.2%
General Public1,126,516,73539.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 7 shareholders own 60.53% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20.41%
All Favour Holdings Limited
582,547,765HK$70.5m0%no data
19.29%
Chuang Wang
550,520,000HK$66.6m2.2%no data
9.19%
Changzhou Yaoguang Enterprise Management Consulting Limited Liability Partnership
262,400,000HK$31.8m0%no data
5.63%
Changzhou Zhongmin Xingkong Business Management Consulting Service Partnership Enterprise
160,600,000HK$19.4m0%no data
5.24%
Xiaogang Wang
149,450,000HK$18.1m0%no data
0.75%
Ren Li
21,380,000HK$2.6m0%no data
0.031%
Yumin Dai
875,000HK$105.9k0%no data

Company Information

China Regenerative Medicine International Limited's employee growth, exchange listings and data sources


Key Information

  • Name: China Regenerative Medicine International Limited
  • Ticker: 8158
  • Exchange: SEHK
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$353.932m
  • Shares outstanding: 2.85b
  • Website: https://www.crmi.hk

Number of Employees


Location

  • China Regenerative Medicine International Limited
  • Miramar Tower
  • Suite 2310-2318
  • Tsim Sha Tsui
  • Kowloon
  • Hong Kong


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
8158SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJul 2001

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/29 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.